Related references
Note: Only part of the references are listed.Cholangiocarcinoma: Current Knowledge and New Developments
Boris Blechacz
GUT AND LIVER (2017)
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers
Elizabeth R. Kessler et al.
INVESTIGATIONAL NEW DRUGS (2016)
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. W. Valle et al.
ANNALS OF ONCOLOGY (2016)
Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma
Kulthida Vaeteewoottacharn et al.
TUMOR BIOLOGY (2016)
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma
Giuliana Cavalloni et al.
ONCOTARGET (2016)
YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors
Patricia Marti et al.
HEPATOLOGY (2015)
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data
Lorenzo Fornaro et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
Juan W. Valle et al.
LANCET ONCOLOGY (2015)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
Jean-Florian Guion-Dusserre et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma
Qingbao Cheng et al.
SCIENTIFIC REPORTS (2015)
HIF-1α pathway: role, regulation and intervention for cancer therapy
Georgina N. Masoud et al.
ACTA PHARMACEUTICA SINICA B (2015)
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
A. Santoro et al.
ANNALS OF ONCOLOGY (2015)
Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy
Chantal Dreyer et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumours
N Dey et al.
BRITISH JOURNAL OF CANCER (2014)
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
A. B. El-Khoueiry et al.
BRITISH JOURNAL OF CANCER (2014)
Tumor necrosis factor-α promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-κB-mediated upregulation of vascular endothelial growth factor-C
Qiang Du et al.
CANCER SCIENCE (2014)
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
M. Moehler et al.
EUROPEAN JOURNAL OF CANCER (2014)
Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment
Afsaneh Barzi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Axitinib (AG-013736), an Oral Specific VEGFR TKI, Shows Potential Therapeutic Utility Against Cholangiocarcinoma
Hiroyuki Takahashi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2014)
Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis
Jimme K. Wiggers et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater et al.
JOURNAL OF HEPATOLOGY (2014)
Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo
Dongsheng Xu et al.
ONCOLOGY REPORTS (2014)
Angiopoietin-2 and Biliary Diseases: Elevated Serum, but Not Bile Levels Are Associated with Cholangiocarcinoma
Torsten Voigtlaender et al.
PLOS ONE (2014)
miR-101 Inhibits Cholangiocarcinoma Angiogenesis through Targeting Vascular Endothelial Growth Factor (VEGF)
Jinqiang Zhang et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
J. K. Lee et al.
BRITISH JOURNAL OF CANCER (2013)
CD146, a multi-functional molecule beyond adhesion
Zhaoqing Wang et al.
CANCER LETTERS (2013)
Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
Daniela Sia et al.
GASTROENTEROLOGY (2013)
Platelet-Derived Growth Factor-D and Rho GTPases Regulate Recruitment of Cancer-Associated Fibroblasts in Cholangiocarcinoma
Massimiliano Cadamuro et al.
HEPATOLOGY (2013)
Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells
Do Hyung Kim et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2013)
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers
Waraporn Chan-on et al.
NATURE GENETICS (2013)
Inhibition of Tumor Angiogenesis by Interferon-gamma by Suppression of Tumor-Associated Macrophage Differentiation
Tao Sun et al.
ONCOLOGY RESEARCH (2013)
Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer
Wei Lin et al.
CANCER LETTERS (2012)
A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study
Jun Ho Yi et al.
EUROPEAN JOURNAL OF CANCER (2012)
Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors
Jesper B. Andersen et al.
GASTROENTEROLOGY (2012)
Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma
Heather Francis et al.
GUT (2012)
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
Shahid A. Khan et al.
GUT (2012)
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
Anthony B. El-Khoueiry et al.
INVESTIGATIONAL NEW DRUGS (2012)
Exome sequencing of liver fluke-associated cholangiocarcinoma
Choon Kiat Ong et al.
NATURE GENETICS (2012)
Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma
Wenjun Wang et al.
TUMOR BIOLOGY (2012)
Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma
Sirintip Boonjaraspinyo et al.
TUMOR BIOLOGY (2012)
Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways
Suksanti Prakobwong et al.
CARCINOGENESIS (2011)
Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis
Suksanti Prakobwong et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Tanios Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells
Hiroaki Sugiyama et al.
JOURNAL OF GASTROENTEROLOGY (2011)
HCC and angiogenesis: possible targets and future directions
Andrew X. Zhu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Clinical diagnosis and staging of cholangiocarcinoma
Boris Blechacz et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma
Xiao-Nan Sun et al.
TUMOR BIOLOGY (2011)
Tumor-Associated Angiogenesis and Lymphangiogenesis Correlate With Progression of Intrahepatic Cholangiocarcinoma
Armin Thelen et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
C. Bengala et al.
BRITISH JOURNAL OF CANCER (2010)
Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma
Horlad Hasita et al.
CANCER SCIENCE (2010)
Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
Sam J. Lubner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
Andrew X. Zhu et al.
LANCET ONCOLOGY (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
D. Yoshikawa et al.
BRITISH JOURNAL OF CANCER (2009)
Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas
Nathalie Guedj et al.
JOURNAL OF HEPATOLOGY (2009)
H3 Histamine Receptor-Mediated Activation of Protein Kinase Cα Inhibits the Growth of Cholangiocarcinoma In vitro and In vivo
Heather Francis et al.
MOLECULAR CANCER RESEARCH (2009)
Drug resistance associated with antiangiogenesis therapy
Hans Petter Eikesdal et al.
SEMINARS IN CANCER BIOLOGY (2009)
Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase
Yukari Harino et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2008)
Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma
Armin Thelen et al.
JOURNAL OF GASTROENTEROLOGY (2008)
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
D. Yoshikawa et al.
BRITISH JOURNAL OF CANCER (2008)
Tumour-associated angiogenesis in human colorectal cancer
K. A. Rmali et al.
COLORECTAL DISEASE (2007)
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
M Presta et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: Implications for biliary tract carcinogenesis
JH Yoon et al.
HEPATOLOGY (2004)
Vascular endothelial growth factor: Basic science and clinical progress
N Ferrara
ENDOCRINE REVIEWS (2004)
Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas
A Giatromanolaki et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2003)
Tumorigenesis and the angiogenic switch
G Bergers et al.
NATURE REVIEWS CANCER (2003)
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
A Mantovani et al.
TRENDS IN IMMUNOLOGY (2002)
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
GL Niu et al.
ONCOGENE (2002)
Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation.
KN Meadows et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis
M Jaiswal et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2001)
Share Paper
